Literature DB >> 1171684

Purification and some characteristics of the coagulation factor IX from human plasma.

B Osterud, R Flengsrud.   

Abstract

Non-activated coagulation factor IX was purified approx. 10,000-fold from human plasma. The final product was electrophoretically homogeneous and comprised a tingle polypeptide chain with a molecular weight of about 70,000 and a pI of 4.3-4.45. The N-terminal amino acid was glycine. The amino acid and the carbohydrate contents were analysed and a monospecific antiserum to the factor was raised in rabbits.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1171684      PMCID： PMC1165246          DOI： 10.1042/bj1450469

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


  26 in total

1.  The thiobarbituric acid assay of sialic acids.

Authors:  L WARREN
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

2.  DISC ELECTROPHORESIS. I. BACKGROUND AND THEORY.

Authors:  L ORNSTEIN
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Formation of intrinsic factor-X activator activity, with special reference to the role of thrombin.

Authors:  B Osterud; S I Rapaport; S Schiffman; M M Chong
Journal:  Br J Haematol       Date:  1971-12       Impact factor: 6.998

5.  Isolation and characterization of bovine factor IX (Christmas factor).

Authors:  K Fujikawa; A R Thompson; M E Legaz; R G Meyer; E W Davie
Journal:  Biochemistry       Date:  1973-11-20       Impact factor: 3.162

6.  The protein component of human brain thromboplastin.

Authors:  E Bjorklid; E Storm; H Prydz
Journal:  Biochem Biophys Res Commun       Date:  1973-12-10       Impact factor: 3.575

7.  The separation of clotting factors. II. Purification of human factor IX by isoelectric focusing.

Authors:  S Chandra; L Pechet
Journal:  Biochim Biophys Acta       Date:  1973-12-06

8.  A comparison of bovine prothrombin, factor IX (Christmas factor), and factor X (Stuart factor).

Authors:  K Fujikawa; M H Coan; D L Enfield; K Titani; L H Ericsson; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1974-02       Impact factor: 11.205

9.  Gel filtration properties of factors II, VII, IX, IX a , and X.

Authors:  B Osterud; S Schiffman
Journal:  Thromb Diath Haemorrh       Date:  1972-10-31

10.  The localization of a vitamin K-induced modification in an N-terminal fragment of human prothrombin.

Authors:  T Skotland; T Holm; B Osterud; R Flengsrud; H Prydz
Journal:  Biochem J       Date:  1974-10       Impact factor: 3.857
View more
  8 in total

1.  Gene therapy for hemophilia: the clot thickens.

Authors:  Katherine A High
Journal:  Hum Gene Ther       Date:  2014-11       Impact factor: 5.695

2.  Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.

Authors:  B Osterud; S I Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

3.  Mini-review on "A novel one-step purification of mouse factor IX".

Authors:  Sumita Choudhury; William E Plautz; Cosette Zacarias; Rinku Majumder
Journal:  J Rare Dis Res Treat       Date:  2016

4.  Activation of human factor IX (Christmas factor).

Authors:  R G Di Scipio; K Kurachi; E W Davie
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

5.  Comparison of amino acid sequence of bovine coagulation Factor IX (Christmas Factor) with that of other vitamin K-dependent plasma proteins.

Authors:  K Katayama; L H Ericsson; D L Enfield; K A Walsh; H Neurath; E W Davie; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

6.  Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII.

Authors:  U Seligsohn; B Osterud; S F Brown; J H Griffin; S I Rapaport
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

7.  Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.

Authors:  K S Chung; D A Madar; J C Goldsmith; H S Kingdon; H R Roberts
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

8.  Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.

Authors:  A R Thompson
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.